Jaguar Animal Health Inc logo

Jaguar Animal Health Inc(JAGX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.42
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for JAGX

11/13/2026: JAGX (1-star) is currently NOT-A-BUY. Pass it for now.

Jaguar Animal Health is a micro-cap biotechnology company focused on developing plant-derived gastrointestinal products for companion and production animals. The company benefits from a differentiated botanical drug platform and targeted product candidates like Canalevia and Equilevia. However, its investment story is constrained by persistent net losses, tight working capital, and heavy dilution risks. Primary risks include intense competition from multinational veterinary giants and ongoing execution hurdles. The stock suits speculative investors with high risk tolerance, while key developments to monitor include commercial adoption trends and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitRevenue growth has been subdued and inconsistent relative to the high-risk biotech profile.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp, speculative short-term price movements on clinical or financing news when upturn signals occur.
Value investorWeak fitOngoing net losses and balance sheet strain preclude traditional value investing metrics.
Dividend investorWeak fitThe company pays no dividends and retains all capital for survival and development.
Low-risk investorWeak fitHigh price volatility, dilution risk, and micro-cap status expose investors to severe downside risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap status and low liquidity drive extreme daily percentage price swings.
Valuation riskHighTraditional valuation multiples are distorted by persistent operating losses and low market capitalization.
Competition risk (Large-cap animal health dominance)HighWell-funded competitors dominate veterinary distribution channels and marketing scale.
Business qualityLowEarly commercial scale and financial losses reflect a highly speculative business quality profile.
Dividend incomeLow / noneNo dividend is paid or anticipated in the foreseeable future.
Execution riskHighThe company must successfully navigate clinical, regulatory, and commercial hurdles with limited cash.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.59M USD
Price to earnings Ratio -
1Y Target Price 262.5
Price to earnings Ratio -
1Y Target Price 262.5
Volume (30-day avg) 2.4M shares
Beta -0.12
52 Weeks Range 0.36 - 1039.50
Updated Date 11/15/2026
52 Weeks Range 0.36 - 1039.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -4012.65

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -36.43%
Avg. Invested days 11
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
JAGX receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, and soft company fundamentals.

Company Fundamentals

★★★★★
JAGX has soft overall fundamentals (2 stars), with soft financial health, moderate growth momentum, and soft ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-38.8%), weak cash generation (FCF margin -206.0%), slightly negative revenue growth (-1.5%).

Financial Health Rating

★★★★★
JAGX's financial health is soft, with the relatively strongest area being soft liquidity, including working-capital and asset support (WC/assets -53.0%). Overall financial-health metrics support a 2-star score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is JAGX's strongest growth driver at +19.9% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (-1.5%, slightly negative) and earnings growth (-38.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.3% (soft) and 2.2% of outstanding shares are publicly tradable (soft). Insider ownership is only 0.72%, which materially reduces the ownership score.

Top 5 Institutional Investors

UBS Group AG 0.05%
Tower Research Capital LLC 0.01%
SBI Securities Co Ltd 0.00%
Barclays PLC 0.00%
Royal Bank of Canada 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
JAGX generates approximately $672 of gross profit, $-3,919 of operating income, and $-2,060 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.78%

Quantitative Style Profile

★★★★★
JAGX has a relatively low-volatility profile. No single quantitative factor dominates as a drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Animal Health SegmentRevenues derived from the sale of prescription and non-prescription veterinary products like Canalevia and Equilevia.Sales of specialized animal wellness and gastrointestinal products form the core direct revenue stream for this division.
Geographic Exposure (United States)The vast majority of commercial sales and distribution activities are concentrated within the United States market.The company is heavily dependent on domestic veterinary adoption and regulatory clearance.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 200
Enterprise Value 20.04M
Price to Sales(TTM) 0.2
Enterprise Value 20.04M
Price to Sales(TTM) 0.2
Enterprise Value to Revenue 0.72
Enterprise Value to EBITDA -0.63
Shares Outstanding 13.35M
Shares Floating 289.49K
Shares Outstanding 13.35M
Shares Floating 289.49K
Percent Insiders 0.72
Percent Institutions 0.34

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.